TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26889783
Drug: Virgin Olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virgin Olive Oil complemented with thyme phenolic compounds (FVOOT)
Study: 25862517
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with capecitabine and bevacizumab
Study: 16432265
Drug: Ramelteon 64
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon 64 mg
Study: 9015519
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ivermectin (LDIC group)
Study: 10192639
Drug: Tacrine hydrochloride
Normalized name: Tacrine Hydrochloride
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrine hydrochloride (maximum dose administered for 30 weeks)
Study: 12698087
Drug: Sirolimus (SRL)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (SRL) 2 mg/day with early withdrawal of CsA (group II)
Study: 21336155
Drug: pilocarpine 1%
Normalized name: PILOCARPINE 1% SOLN,OPH
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pilocarpine 1% 4 times daily
Study: 11685491
Drug: Low-dose therapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose therapy (60 Gy)
Study: 511533
Drug: Clonazepam (Rivotril)
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonazepam (Rivotril) 2 mg per day
Study: 1986730
Drug: Thiamine at
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine at 3 g/d
Study: 333252
Drug: Doxepin 75
Normalized name: doxepin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin 75 mg daily for 14 days
Study: 7752826
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ), 3.0‐3.4 mg/kg/day for 7 days
Study: 3512031
Drug: Conventional low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional low-dose heparin
Study: 24363238
Drug: Frovatriptan 2.5
Normalized name: frovatriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan 2.5 mg alone (Frova)
Study: 6363970
Drug: Central anticholinergic
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central anticholinergic therapy
Study: 27181790
Drug: Bremelanotide (BMT)
DrugBank: Bremelanotide (DB11653)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bremelanotide (BMT) 1.25/1.75 mg
Study: 2997092
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (prednisone for six days)
Study: 17562035
Drug: Combination (CM)
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (CM)
Study: 21289226
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D + calcium-fortified yogurt drink (DCY; containing 500 IU vitamin D(3) and 250 mg Ca/250 mL)
Study: 19337745
Drug: Acetazolamide 125
Normalized name: acetazolamide 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 125 mg (ACZ)
Study: 16325084
Drug: Transfemoral fixation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfemoral fixation implant (Transfix; Arthrex) and interference screw (Arthrex) in the tibial tunnel
Study: 2250075
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied fluorescein gel
Study: 30780194
Drug: Standard-dose clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose clarithromycin group (esomeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid, bismuth potassium citrate 0.6 g bid) for 14 days
Study: 8295604
Drug: Dihydroergotamine tartrate
Normalized name: dihydroergotamine tartrate
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine tartrate (DHE) 2 mg
Study: 15174232
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta 1a (Avonex) treatment, 30 mcg once a week
Study: 6135029
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of CyA dose
Study: 17634487
Drug: Short-term androgen-deprivation
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term androgen-deprivation therapy (STAD) plus radiotherapy (RT)
Study: 26247960
Drug: EPA +
Normalized name: Eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPA + DHA supplementation (0-4 portions of oily fish/week, equivalent to 3.27 g EPA+DHA per portion)
Study: 18815665
Drug: Amiodarone (AMD)
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiodarone (AMD) treatment
Study: 8786016
Drug: ALA 600
Normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA 600 mg
Study: 26690825
Drug: High visceral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High visceral fat to subcutaneous fat ratio (VFA/SFA)
Study: 31342566
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of lingonberry extract and 60 mg of amla fruit extract
Study: 2087535
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone releasing factor (GRF) 1 microgram/kg
Study: 25778933
Drug: Quarter dose
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarter dose combination (paracetamol 250 mg and ibuprofen 75 mg)
Study: 16728451
Drug: BT +
Normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT + L-NAME
Study: 8149518
Drug: Intensive cholesterol-lowering
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive cholesterol-lowering treatment for 90 days
Study: 10582974
Drug: Serum total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum total cholesterol > or = 7.0 mmol/L
Study: 31264757
Drug: Efpeglenatide 6
Normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide 6 mg once every 2 weeks
Study: 29450452
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy alone
Study: 8823470
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus 13‐cis‐retinoic acid (RA)
Study: 28859020
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs for 2 weeks
Study: 16875041
Drug: Low-Carbohydrate Diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Carbohydrate Diet (< 30 g/day)
Study: 10687523
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of flurbiprofen and tramadol
Study: 15480643
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy at energy level E1=0.15 mJ/mm2
Study: 22456294
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg administered 30 min before meals
Study: 19115653
Drug: Lumbar wedge
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumbar wedge (group L)
Study: 17717285
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy
Study: 22699129
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine 1.5 mg/kg bolus followed by continuous infusion of 1.5 mg/kg/h, stopped 1 hour after skin closure
Study: 28545041
Drug: Early measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early measles vaccine (MV) at 18 weeks of age
Study: 8163828
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses
Study: 26239482
Drug: Caffeine and
Normalized name: caffeine and sodium benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine and albuterol
Study: 9140151
Drug: 13C-urea breath
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 13C-urea breath test (UBT) with 75 mg 13C-urea and citric acid
Study: 15088864
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of diazepam
Study: 15204893
Drug: Life Review
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life Review Therapy (3 one-hour sessions)
Study: 29392846
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow nasal cannulae (HFNC) therapy
Study: 30400924
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) supplement for 6 weeks
Study: 7740443
Drug: Dermatan sulphate
Normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulphate 200 mg once daily
Study: 8601548
Drug: Haloperidol 0.2
Normalized name: haloperidol 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 0.2 mg/kg/day
Study: 18516012
Drug: Levofloxacin 300
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 300 mg, amoxicillin 1 g, and pantoprazole 20 mg, given twice daily for 7 days (LAP group)
Study: 12749965
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine (50 microg/kg/min over 60min)
Study: 16642606
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at 'Kaiyin point No. 1', once daily for 7 days.
Study: 11502788
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (Premarin, 0.625 mg/d)
Study: 23537965
Drug: Clinical pharmacy
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacy specialist-, telephone-administered intervention
Study: 30213173
Drug: Postoperative parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Postoperative parecoxib administration (40 mg at wound closure and at 12 and 24 hours after the first dose)
Study: 8881624
Drug: Thiopentone 4
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 4 mg kg‐1
Study: 12855302
Drug: Smaller stride
Normalized name: Stridex
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smaller stride length (L)
Study: 29676980
Drug: medium viscosity
Normalized name: LUBRICANT,SIL-OPHTHO MEDIUM VISCOSITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: medium viscosity gel without HP (negative control)
Study: 29433493
Drug: Integrated Individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Individual Placement and Support (IPS) with pain treatment
Study: 20075952
Drug: Epoetin-alfa treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin-alfa treatment to a target hemoglobin level of 13.5 g/dl
Study: 17392660
Drug: Alcohol septal
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol septal ablation (ASA) - 1-3 ml of absolute alcohol introduced into the septal branch to create a controlled septal infarction.
Study: 29888938
Drug: Hypnotic suggestion
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestion for alien control
Study: 31759909
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of a legume-based food product administered daily for three months (5 days on, 2 days off)
Study: 30650265
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese herbal medicine ointment
Study: 19678919
Drug: Study therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study therapy initiation and volume management
Study: 8768841
Drug: GHRH administration
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH administration after transdermal estrogens
Study: 1847128
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy (HFX) with total doses of 69.6 Gy
Study: 19216446
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (bolus 50 mg/kg and 0.5 g/h)
Study: 22395054
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (control group)
Study: 18691778
Drug: Normal potassium
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal potassium (4-4.9 mEq/L)
Study: 18691778
Drug: Low-normal potassium
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-normal potassium (3.5-3.9 mEq/L)
Study: 16551916
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (continuous naropine infusion)
Study: 9457283
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with the Dornier Urowave device
Study: 9141923
Drug: ORG 9487
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 9487 (up to 2.0 mg/kg for adults, up to 1.5 mg/kg for elderly)
Study: 19625715
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine
Study: 17076982
Drug: IM aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IM aripiprazole 9.75 mg
Study: 19111849
Drug: IM aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IM aripiprazole 15 mg
Study: 9796594
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (20 minutes daily for 1 month)
Study: 8035026
Drug: SPf66 malaria
Normalized name: PLASMODIUM MALARIAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66 malaria vaccine (three doses on days 0, 20, and 112)
Study: 24395557
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate 800 mg
Study: 6433769
Drug: HB 419
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HB 419 (5 mg)
Study: 2083404
Drug: Choline magnesium
Normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choline magnesium trisalicylate (CMT, trilisate) pre-treatment
Study: 14699020
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.8 mg), vitamin B12 (0.4 mg), and vitamin B6 (40 mg)
Study: 21389855
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.8 mg) and vitamin B12 (0.4 mg)
Study: 11929645
Drug: Both contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both contraceptive treatments
Study: 26175027
Drug: TDEN vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDEN vaccine (two formulations)
Study: 8259754
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol therapy (Estraderm 50 micrograms/24h)
Study: 7707852
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution
Study: 10883747
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (180 microg four times daily for 7 days)
Study: 26026121
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (36 mg/m2, days 1 and 8)
Study: 12802750
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with lamivudine (100 mg daily) and IFN‐alpha‐2b (10 million U 3 times per week for 12 months)
Study: 9256568
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (TNP; 21 mg)
Study: 9256568
Drug: Self-help treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help treatment manual only
Study: 8476802
Drug: 45 min
Normalized name: ZINC OXIDE 19 g in 100 mL TOPICAL LOTION [Meadow and Bark SPF 45 Mineral Sport Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 min incremental oxytocin infusion
Study: 23196892
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia (SPA) with 7.5 mg hyperbaric bupivacaine
Study: 23196892
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with Propofol and Fentanyl
Study: 9382539
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion chemotherapy with 5-FU + MMC +/- ADR (Group I)
Study: 9382539
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion chemotherapy in primary cases
Study: 9382539
Drug: All cases
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All cases of intra-arterial infusion chemotherapy
Study: 9382539
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion chemotherapy with catheter tip in internal iliac arteries
Study: 8566980
Drug: Podophyllotoxin solution
Normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Podophyllotoxin solution 0.5% (Condyline)
Study: 1173042
Drug: Xipamide (4-chloro-5-sulfamoyl-2',6'-salicyloxylidide)
Normalized name: xipamide
DrugBank: Xipamide (DB13803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xipamide (4-chloro-5-sulfamoyl-2',6'-salicyloxylidide) administered orally in doses ranging from 0.035 to 0.750 mg/kg body weight
Study: 29187186
Drug: Current DM
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current DM treatment standards (Control)
Study: 9613683
Drug: Filgrastim 5
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim 5 microg/kg/dy after intensive sequential chemotherapy
Study: 27759930
Drug: Intermittent Cyclical
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Cyclical Etidronate Therapy
Study: 2905256
Drug: roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine acetate 75 mg twice daily
Study: 19951520
Drug: Nasal inhaled
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal inhaled corticosteroid (ICS) through a spacer with mask (budesonide inhaler 400 microg/d)
Study: 19951520
Drug: Orally inhaled
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally inhaled budesonide dry powder (400 microg/d) plus nasal spray of budesonide aquae (256 microg/d)
Study: 15364229
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate ophthalmic suspension, 0.5%, 4 times a day for 4 weeks
Study: 10867675
Drug: Residual of
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual of the regression of actual treatment indicator on randomization arm indicator
Study: 31706541
Drug: Autologous platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet-rich gel (APG)
Study: 5441886
Drug: Intravenous secretin
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous secretin (2 units per kilogram per hour)